1
/
of
1
Imatero (Imatinib)
Imatero (Imatinib)
Regular price
₱6,750.00 PHP
Regular price
Sale price
₱6,750.00 PHP
Unit price
₱112.50 each
Taxes included.
Quantity
Couldn't load pickup availability
Imatero (Imatinib) – Targeted Tyrosine Kinase Inhibitor for Blood Cancers and Solid Tumors
Imatero contains imatinib, a breakthrough tyrosine kinase inhibitor (TKI) that represents a cornerstone of targeted cancer therapy. Unlike traditional chemotherapy that damages rapidly dividing cells indiscriminately, imatinib works by selectively blocking abnormal signaling proteins—most notably BCR-ABL—that drive cancer cell growth and proliferation. This mechanism of action allows imatinib to suppress malignant cell division while minimizing harm to healthy tissues, making it a foundational treatment in modern oncology.
Imatero is prescribed for a broad spectrum of hematologic malignancies and solid tumors where specific kinase mutations are present. These include chronic myeloid leukemia (CML) with Philadelphia chromosome positivity, acute lymphoblastic leukemia (ALL) in Ph+ cases, gastrointestinal stromal tumors (GISTs) expressing c-KIT (CD117) mutations, myelodysplastic and myeloproliferative diseases carrying PDGFR alterations, hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), and dermatofibrosarcoma protuberans (DFSP). The drug's efficacy in these indications has transformed outcomes for patients with otherwise aggressive malignancies.
Imatero is contraindicated in patients with documented hypersensitivity to imatinib or any formulation component. Pregnancy and breastfeeding are absolute contraindications due to risk of fetal harm. Caution is essential in patients with severe hepatic impairment, as imatinib undergoes hepatic metabolism, and in those with underlying cardiac disease, given the potential for fluid retention and heart failure.
Dosage must be individualized based on diagnosis, disease stage, and physician assessment. Always consult your healthcare provider before starting, adjusting, or discontinuing Imatero. This medication requires regular medical supervision to monitor efficacy and manage potential adverse effects.
Imatero contains imatinib, a breakthrough tyrosine kinase inhibitor (TKI) that represents a cornerstone of targeted cancer therapy. Unlike traditional chemotherapy that damages rapidly dividing cells indiscriminately, imatinib works by selectively blocking abnormal signaling proteins—most notably BCR-ABL—that drive cancer cell growth and proliferation. This mechanism of action allows imatinib to suppress malignant cell division while minimizing harm to healthy tissues, making it a foundational treatment in modern oncology.
Imatero is prescribed for a broad spectrum of hematologic malignancies and solid tumors where specific kinase mutations are present. These include chronic myeloid leukemia (CML) with Philadelphia chromosome positivity, acute lymphoblastic leukemia (ALL) in Ph+ cases, gastrointestinal stromal tumors (GISTs) expressing c-KIT (CD117) mutations, myelodysplastic and myeloproliferative diseases carrying PDGFR alterations, hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), and dermatofibrosarcoma protuberans (DFSP). The drug's efficacy in these indications has transformed outcomes for patients with otherwise aggressive malignancies.
Imatero is contraindicated in patients with documented hypersensitivity to imatinib or any formulation component. Pregnancy and breastfeeding are absolute contraindications due to risk of fetal harm. Caution is essential in patients with severe hepatic impairment, as imatinib undergoes hepatic metabolism, and in those with underlying cardiac disease, given the potential for fluid retention and heart failure.
Dosage must be individualized based on diagnosis, disease stage, and physician assessment. Always consult your healthcare provider before starting, adjusting, or discontinuing Imatero. This medication requires regular medical supervision to monitor efficacy and manage potential adverse effects.
Share
